{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 30 of 128', 'Screening', 'Treatment period', 'Follow-', 'Primary', 'Unscheduled', 'References', 'End of treatment/', 'up4', 'endpoint', 'visit, if', '(protocol', 'early termination\u00b3', 'visit at', 'applicable6', 'section)', 'Week 16,', 'Visit', '1', '2', '3\u00b2', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', 'if', 'Week', '-4 to -1', '0', '1', '2', '4', '6', '8', '10', '12', '14', '16', '18', 'applicable5', 'Day', '-28 to -7', '1', '4', '8', '15', '29', '43', '57', '71', '85', '99', '113', '127', 'Visit window (days\u00b9', '-', '-', '1', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', 'WLQ12', 'X', 'X', 'X', 'X', 'X', '11.7.1.8', 'Investigator assessments of efficacy', 'IGA', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '11.3.1', 'HECSI', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '11.3.2', 'Investigator assessments of safety', 'Vital signs', 'X', 'X', 'X', '(X)', '11.4.1', 'Physical examination', 'X', 'X', '(X)', '11.4.2', 'ECG', 'X', 'X', '(X)', '11.4.3', 'Chemistry, haematology13', 'X', 'X', '(X)', '11.4.4', 'Serology, total IgE,', '11.4.4', 'tuberculosis test14', 'X', 'Serum pregnancy test15', 'X', '(X)', '11.4.4', 'Urine pregnancy test15', 'X', '(X)', '11.4.4', 'Urinalysis - dipstick', 'X', 'X', '(X)', '11.4.4', 'AEs/SAEs', 'X', 'X16', 'X', 'X', 'X', 'X', 'X', 'X', '13', 'Subject assessment of local', 'X', 'X', 'X', '11.4.5', 'tolerability']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 31 of 128', 'Screening', 'Treatment period', 'Follow-', 'Primary', 'Unscheduled', 'References', 'End of treatment/', 'up4', 'endpoint', 'visit, if', '(protocol', 'early termination\u00b3', 'visit at', 'applicable6', 'section)', 'Week 16,', 'Visit', '1', '2', '3\u00b2', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', 'if', 'Week', '-4 to -1', '0', '1', '2', '4', '6', '8', '10', '12', '14', '16', '18', 'applicable5', 'Day', '-28 to -7', '1', '4', '8', '15', '29', '43', '57', '71', '85', '99', '113', '127', 'Visit window (days\u00b9', '-', '-', '1', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', 'Other assessments', 'PK blood sample', 'X17', '11.5.1', 'Skin swab/skin microbiome', 'X', '11.6.2', 'Blood sample for filaggrin', 'X', '11.6.4', 'mutation status', 'Skin barrier function', 'X19', 'X', '11.6.5', '(selected sites18, 19', 'Skin biopsy and', 'X19', 'X20', '11.6.3', 'photography (optional) 19', 'Check skin biopsy wound', 'X', '11.6.3', 'healing/suture removal', 'New chronic hand eczema', 'X', 'X', 'X', 'X', '9.2', 'lesions', 'Return of eDiary', 'X', 'End of trial form21', 'X', 'X', 'X', '10.3, 11.9', '1)', 'If the date of a trial visit does not conform to the clinical trial protocol, subsequent visits should be planned to maintain the visit schedule relative to baseline/randomisation', 'at', 'Day 1.', '2)', 'A visit at the trial site is not required on Day 4, a member of trial site personnel will call the subjects.', '3) End of treatment assessments will be conducted at Week 16.', 'Early termination: subjects, who discontinue IMP treatment prior to Week 16 or withdraw from trial will be asked to return to the trial site for end of treatment assessments at an']\n\n###\n\n", "completion": "END"}